Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

Cisplatin Nephrotoxicity and Longitudinal Growth in Children With Solid Tumors: A Retrospective Cohort Study.

Jiménez-Triana CA, Castelán-Martínez OD, Rivas-Ruiz R, Jiménez-Méndez R, Medina A, Clark P, Rassekh R, Castañeda-Hernández G, Carleton B, Medeiros M; Canadian Pharmacogenomics Network for Drug Safety Consortium.

Medicine (Baltimore). 2015 Aug;94(34):e1413. doi: 10.1097/MD.0000000000001413.

2.

A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.

Aminkeng F, Bhavsar AP, Visscher H, Rassekh SR, Li Y, Lee JW, Brunham LR, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Amstutz U, Rieder MJ, Bernstein D, Carleton BC, Hayden MR, Ross CJ; Canadian Pharmacogenomics Network for Drug Safety Consortium.

Nat Genet. 2015 Sep;47(9):1079-84. doi: 10.1038/ng.3374. Epub 2015 Aug 3.

3.

Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children.

Visscher H, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Rogers PC, Rieder MJ, Carleton BC, Hayden MR, Ross CJ; CPNDS consortium.

Pharmacogenomics. 2015;16(10):1065-76. doi: 10.2217/pgs.15.61. Epub 2015 Jul 31.

PMID:
26230641
4.

Genetic markers of cisplatin-induced hearing loss in children.

Carleton BC, Ross CJ, Pussegoda K, Bhavsar AP, Visscher H, Lee JW, Brooks B, Rassekh SR, Dubé MP, Hayden MR.

Clin Pharmacol Ther. 2014 Sep;96(3):296-8. doi: 10.1038/clpt.2014.92.

PMID:
25141953
5.

Response to "evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity".

Carleton BC, Ross CJ, Bhavsar AP, Lee JW, Visscher H, Rassekh SR, Hayden MR.

Clin Pharmacol Ther. 2014 Aug;96(2):158. doi: 10.1038/clpt.2014.90. Epub 2014 Apr 22. No abstract available.

PMID:
24755913
6.

Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity.

Carleton BC, Ross CJ, Bhavsar AP, Amstutz U, Pussegoda K, Visscher H, Lee JW, Brooks B, Rassekh SR, Dubé MP, Hayden MR.

Clin Pharmacol Ther. 2014 Mar;95(3):253. doi: 10.1038/clpt.2013.219. Epub 2013 Nov 5. No abstract available.

PMID:
24193170
7.

Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children.

Pussegoda K, Ross CJ, Visscher H, Yazdanpanah M, Brooks B, Rassekh SR, Zada YF, Dubé MP, Carleton BC, Hayden MR; CPNDS Consortium.

Clin Pharmacol Ther. 2013 Aug;94(2):243-51. doi: 10.1038/clpt.2013.80. Epub 2013 Apr 10.

8.

Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent.

Aminkeng F, Ross CJ, Rassekh SR, Brunham LR, Sistonen J, Dube MP, Ibrahim M, Nyambo TB, Omar SA, Froment A, Bodo JM, Tishkoff S, Carleton BC, Hayden MR; Canadian Pharmacogenomics Network for Drug Safety Consortium.

Pharmacogenomics J. 2014 Apr;14(2):160-70. doi: 10.1038/tpj.2013.13. Epub 2013 Apr 16.

9.

Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children.

Visscher H, Ross CJ, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Rogers PC, Rieder MJ, Carleton BC, Hayden MR; CPNDS Consortium.

Pediatr Blood Cancer. 2013 Aug;60(8):1375-81. doi: 10.1002/pbc.24505. Epub 2013 Feb 25.

PMID:
23441093
10.

Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.

Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dubé MP, Al-Saloos H, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Brown AM, Rogers PC, Phillips MS, Rieder MJ, Carleton BC, Hayden MR; Canadian Pharmacogenomics Network for Drug Safety Consortium.

J Clin Oncol. 2012 May 1;30(13):1422-8. doi: 10.1200/JCO.2010.34.3467. Epub 2011 Sep 6.

PMID:
21900104
11.
12.

Pharmacogenomics of serious adverse drug reactions in pediatric oncology.

Ross CJ, Visscher H, Rassekh SR, Castro-Pastrana LI, Shereck E, Carleton B, Hayden MR.

J Popul Ther Clin Pharmacol. 2011;18:e134-51. Epub 2011 Mar 21. Review.

PMID:
21467604
13.

Pharmacogenomics of cardiovascular drugs and adverse effects in pediatrics.

Visscher H, Amstutz U, Sistonen J, Ross CJ, Hayden MR, Carleton BC.

J Cardiovasc Pharmacol. 2011 Sep;58(3):228-39. doi: 10.1097/FJC.0b013e3182163b82. Review.

PMID:
21386709
14.

HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia.

Warby SC, Visscher H, Collins JA, Doty CN, Carter C, Butland SL, Hayden AR, Kanazawa I, Ross CJ, Hayden MR.

Eur J Hum Genet. 2011 May;19(5):561-6. doi: 10.1038/ejhg.2010.229. Epub 2011 Jan 19.

15.

Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.

Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK, Visscher H, Jukema JW, Stalenhoef AF, Ross CJ, Carleton BC, Kastelein JJ, Hayden MR.

Pharmacogenomics J. 2012 Jun;12(3):233-7. doi: 10.1038/tpj.2010.92. Epub 2011 Jan 18.

PMID:
21243006
16.

Pharmacogenomics and active surveillance for serious adverse drug reactions in children.

Loo TT, Ross CJ, Sistonen J, Visscher H, Madadi P, Koren G, Hayden MR, Carleton BC.

Pharmacogenomics. 2010 Sep;11(9):1269-85. doi: 10.2217/pgs.10.111. Review.

PMID:
20860467
17.

The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology.

Ross CJ, Visscher H, Sistonen J, Brunham LR, Pussegoda K, Loo TT, Rieder MJ, Koren G, Carleton BC, Hayden MR; CPNDS Consortium.

Thyroid. 2010 Jul;20(7):681-7. doi: 10.1089/thy.2010.1642. Review.

PMID:
20578893
18.

Response to Falush: a role for cis-element polymorphisms in HD.

Warby SC, Visscher H, Butland S, Pearson CE, Hayden MR.

Am J Hum Genet. 2009 Dec;85(6):942-5. doi: 10.1016/j.ajhg.2009.11.006. No abstract available.

19.

Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.

Ross CJ, Katzov-Eckert H, Dubé MP, Brooks B, Rassekh SR, Barhdadi A, Feroz-Zada Y, Visscher H, Brown AM, Rieder MJ, Rogers PC, Phillips MS, Carleton BC, Hayden MR; CPNDS Consortium.

Nat Genet. 2009 Dec;41(12):1345-9. doi: 10.1038/ng.478. Epub 2009 Nov 8. Erratum in: Nat Genet. 2013 May;45(5):578.

PMID:
19898482
20.

Application of principal component analysis to pharmacogenomic studies in Canada.

Visscher H, Ross CJ, Dubé MP, Brown AM, Phillips MS, Carleton BC, Hayden MR.

Pharmacogenomics J. 2009 Dec;9(6):362-72. doi: 10.1038/tpj.2009.36. Epub 2009 Aug 4.

PMID:
19652663

Supplemental Content

Loading ...
Support Center